FDA Approves New Indication For Takeda’s Cancer Drug Velcade

The Food and Drug Administration has approved a new indication for the cancer drug Velcade (bortezomib).

Drugmaker Millennium and its parent company, Takeda Pharmaceutical Co., Aug. 8 announced that the FDA has approved Velcade for the re-treatment of adult patients with multiple myeloma who have previously responded to Velcade therapy and relapsed at least six months following completion of prior Velcade treatment.

The labeling update includes dosing guidelines as well as safety and efficacy findings for the use of Velcade as a single agent or Velcade in combination with dexamethasone in patients previously treated with Velcade, the companies said. Velcade ...